Breast angiosarcoma surveillance study: UK national audit of management and outcomes of angiosarcoma of the breast and chest wall
Author
Banks, JGeorge, J
Potter, S
Gardiner, M D
Ives, C
Shaaban, A M
Singh, J
Sherriff, J
Hallissey, M T
Horgan, K
Harnett, A
Desai, A
Ferguson, D J
Tillett, R
Izadi, D
Sadideen, H
Jain, A
Gerrand, C
Holcombe, C
Hayes, A
Teoh, V
Wyld, L
Affiliation
Royal Devon and Exeter Hospital NHS Foundation Trust; University of Sheffield; Sheffield Teaching Hospitals NHS Foundation Trust; North Bristol NHS Trust; Bristol Medical School; Frimley Health Foundation NHS Trust; University of Oxford; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Leeds Teaching Hospitals NHS Trust; Norfolk and Norwich University Hospital NHS Foundation Trust; Imperial College London; Imperial College Healthcare NHS Trust; Royal National Orthopaedic Hospital NHS Trust; British Association of Plastic, Reconstructive and Aesthetic Surgeons; Royal Liverpool and Broadgreen University Hospitals NHS Foundation Trust; Royal Marsden HospitalPublication date
2021-03-22Subject
Oncology. Pathology.
Metadata
Show full item recordAbstract
Background: Breast angiosarcomas are rare tumours of vascular origin. Secondary angiosarcoma occurs following radiotherapy for breast cancer. Angiosarcomas have high recurrence and poor survival rates. This is concerning owing to the increasing use of adjuvant radiotherapy for the treatment of invasive breast cancer and ductal cancer in situ (DCIS), which could explain the rising incidence of angiosarcoma. Outcome data are limited and provide a poor evidence base for treatment. This paper presents a national, trainee-led, retrospective, multicentre study of a large angiosarcoma cohort. Methods: Data for patients with a diagnosis of breast/chest wall angiosarcoma between 2000 and 2015 were collected retrospectively from 15 centres. Results: The cohort included 183 patients with 34 primary and 149 secondary angiosarcomas. Median latency from breast cancer to secondary angiosarcoma was 6 years. Only 78.9 per cent of patients were discussed at a sarcoma multidisciplinary team meeting. Rates of recurrence were high with 14 of 28 (50 per cent ) recurrences in patients with primary and 80 of 124 (64.5 per cent ) in those with secondary angiosarcoma at 5 years. Many patients had multiple recurrences: total of 94 recurrences in 162 patients (58.0 per cent). Median survival was 5 (range 0-16) years for patients with primary and 5 (0-15) years for those with secondary angiosarcoma. Development of secondary angiosarcoma had a negative impact on predicted breast cancer survival, with a median 10-year PREDICT prognostic rate of 69.6 per cent, compared with 54.0 per cent in the observed cohort. Conclusion: A detrimental impact of secondary angiosarcoma on breast cancer survival has been demonstrated. Although not statistically significant, almost all excess deaths were attributable to angiosarcoma. The increased use of adjuvant radiotherapy to treat low-risk breast cancer and DCIS is a cause for concern and warrants further study.Citation
Banks J, George J, Potter S, Gardiner MD, Ives C, Shaaban AM, Singh J, Sherriff J, Hallissey MT, Horgan K, Harnett A, Desai A, Ferguson DJ, Tillett R, Izadi D, Sadideen H, Jain A, Gerrand C, Holcombe C, Hayes A, Teoh V, Wyld L; Breast Angiosarcoma Surveillance Study (BRASS) collaborative. Breast Angiosarcoma Surveillance Study: UK national audit of management and outcomes of angiosarcoma of the breast and chest wall. Br J Surg. 2021 Apr 30;108(4):388-394. doi: 10.1093/bjs/znaa128.Type
ArticleAdditional Links
https://academic.oup.com/bjsPMID
33749771Journal
British Journal of Surgeryae974a485f413a2113503eed53cd6c53
10.1093/bjs/znaa128